Efraín J. Sánchez Angarita (@efrasanchez) header
Efraín J. Sánchez Angarita (@efrasanchez) profile picture

Neumonólogo. Latinoamericano, Venezolano, Caraqueño y Guayaco de adopción. Papá de Coco y Nana Director Departamento EPOC @alatorax 2024-2026.

Guayaquil, Guayas, Ecuador.
Joined January 2010
Photo by Efraín J. Sánchez Angarita (@efrasanchez)Photo by Efraín J. Sánchez Angarita (@efrasanchez)Photo by Efraín J. Sánchez Angarita (@efrasanchez)Photo by Efraín J. Sánchez Angarita (@efrasanchez)Photo by Efraín J. Sánchez Angarita (@efrasanchez)Photo by Efraín J. Sánchez Angarita (@efrasanchez)Photo by Efraín J. Sánchez Angarita (@efrasanchez)Photo by Efraín J. Sánchez Angarita (@efrasanchez)Photo by Efraín J. Sánchez Angarita (@efrasanchez)
Efraín J. Sánchez Angarita retweeted
You’ve heard of the A team How about the ABC team?? Asthma, bronchiectasis and COPD coming together at GOLD2026 ❤️🫁 With my friends Alvar Agusti (GOLD) , Guy Brusselle (GINA) and @EMBARCnetwork
1
6
3
58
2,068
Efraín J. Sánchez Angarita retweeted
Sometimes you have to take a step back and reflect Today there were two major talks on bronchiectasis at the GOLD COPD conference Bronchiectasis now taking centre stage and patient will benefit if we diagnose early and treat properly Keep working together for better patient care ❤️🫁
Global #Patient_registries put #bronchiectasis and its phenotypes like BE #COPD overlap on the map.. BE now featured at #GOLDCOPD2026. Awareness leads to optimal diagnosis and care delivery 👏👏👏 @EMBARCnetwork @ProfJDChalmers
5
35
1,123
Efraín J. Sánchez Angarita retweeted
COPD can no longer wait Proud to have contributed to the updated @TheLancet Commission on COPD, launching November 11! A global call to rethink how we prevent, diagnose, and treat COPD. Join us for the launch hosted by @EuroRespSoc ! @LungAssociation @COPDFoundation @copd_inet @bcmhouston 🔗 ersnet.org/events/copd-can-n…
2
10
24
1,054
Efraín J. Sánchez Angarita retweeted
A new study found that many bronchiectasis patients are not prescribed high frequency chest wall oscillation therapy to improve mucus removal even though it can be reimbursed for many patients. Read more in the Journal of the COPD Foundation: journal.copdfoundation.org/j…
2
2
345
Efraín J. Sánchez Angarita retweeted
Quiero agradecer al presidente Florentino Pérez y a la Junta que me hayan propuesto formar parte de la Junta Directiva del @realmadrid. He aceptado esta propuesta con mucha ilusión, ganas de aprender y aportar todo lo que pueda. 🤍🤍🤍
1,577
12,989
1,247
85,539
1,903,983
Efraín J. Sánchez Angarita retweeted
Three major October headlines from studies published in NEJM: 1️⃣ Weight-loss drug could help address nighttime sleep disruptions for millions (FOX News) nej.md/3UTF6rN Original Article: Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1 and -2) nej.md/4BmAHOI 2️⃣ In small trial, optogenetics restores some vision lost to retinitis pigmentosa (STAT) nej.md/4imhuUB Original Article: Optogenetic Therapy for Restoring Aspects of Visual Function (PIONEER) nej.md/4j18UMZ 3️⃣ Glucose Monitors Can Help Type 2 Diabetics Who Don't Yet Need Insulin, Trial Shows (HealthDay) nej.md/3WSd6W4 Original Article: Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes (CONNECT) nej.md/3TGQNlg Explore impactful research at NEJM.org.
5
8
2
20
8,803
Efraín J. Sánchez Angarita retweeted
#Lungcancer is the world’s leading cause of cancer deaths, and its diagnosis remains challenging. Our mission is to empower physicians to achieve an earlier, more definitive diagnosis.   Learn how Cellvizio advanced imaging improves diagnostic accuracy: hubs.la/Q04D5RQy0
1
1
114
Efraín J. Sánchez Angarita retweeted
🫁 Tabaquismo y vapeo en jóvenes La exposición temprana a nicotina y aerosoles tóxicos puede afectar el desarrollo pulmonar y aumentar el riesgo de dependencia. Vapear no es una alternativa segura. 🔬 Conoce más: alatorax.org/r/sFD8mD/x
5
2
89
Efraín J. Sánchez Angarita retweeted
Discovery of a mechanism to help explain why pulmonary hypertension is linked to cognitive decline. Multiple cohorts and mouse model work shows inflammation (both microglia and endothelial) and a specific mediator @jclinicalinvest jci.org/articles/view/212006 jci.org/articles/view/195110
21
44
4
178
23,139
Efraín J. Sánchez Angarita retweeted
Original Article: Tozorakimab to Prevent COPD Exacerbations (phase 3 OBERON and TITANIA trials) nej.md/4zNqtWJ #Pulmonology #CriticalCare
1
14
1
42
12,761
Efraín J. Sánchez Angarita retweeted
NOVEMBER is COPD Awareness Month 🧡This year, we're celebrating the power of ORANGE as a symbol of the movement to improve lung health. Join us this month as we shine a light on COPD. #COPDAwarenessMonth #November #OrangeIs #COPD #Orange #LungHealth #Advocacy
1
5
4
286
Efraín J. Sánchez Angarita retweeted
On World COPD Day, Wednesday, November 18, one baton travels around the world for 24 hours. Patients, families, clinicians and scientists from around the world are coming together to raise awareness for COPD. Add your voice! Film a 30-second selfie about why COPD matters to you, end with "I am passing the baton on," and upload it here: bit.ly/48o9iyh. Heading to the GOLD COPD Conference in Philadelphia on November 5 and 6? Stop by the "Pass It On" booth and film your video live! For more on World COPD Day, visit bit.ly/4kpcp06 #COPDBatonPass #WorldCOPDDay
4
7
506
Efraín J. Sánchez Angarita retweeted
Here is the clip of the Brewers on SNL tonight: Pat Murphy, Christian Yelich, Brice Turang…and Drunk Uncle👇🤣 🎥: SNL
30
306
12
3,223
197,502
Efraín J. Sánchez Angarita retweeted
More therapeutic options for patients living with #COPD regardless of baseline blood eos
COPD can be associated with exacerbations despite maintenance therapy. Two phase 2 trials tested add-on tozorakimab, a monoclonal antibody that inhibits interleukin-33 activity. Research findings from the phase 3 OBERON and TITANIA trials are summarized in a new Quick Take video. nej.md/47Edhqp
1
4
10
753
Efraín J. Sánchez Angarita retweeted
COPD can be associated with exacerbations despite maintenance therapy. Two phase 2 trials tested add-on tozorakimab, a monoclonal antibody that inhibits interleukin-33 activity. Research findings from the phase 3 OBERON and TITANIA trials are summarized in a new Quick Take video. nej.md/47Edhqp
4
33
5
138
26,493
Efraín J. Sánchez Angarita retweeted
ERJ Open Research: Patients with COPD–obstructive sleep apnoea (OSA) overlap syndrome have a significantly higher cardiovascular mortality compared with OSA alone but not compared with COPD alone, necessitating earlier prevention strategies bit.ly/3QayPpz
2
10
22
1,732